Drug Profile
Research programme: inflammation therapy - Evotec SE/Seikagaku
Latest Information Update: 26 Sep 2019
Price :
$50
*
At a glance
- Originator Evotec AG; Seikagaku Corporation
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 26 Feb 2008 Preclinical development is ongoing
- 13 Aug 2004 Preclinical trials in Inflammation in Europe (unspecified route)